CDK4/6 inhibition is a promising therapeutic approach to treat cancer, but it is challenged by resistance development. Here, the authors show that the RNA binding protein LRPPRC forms a positive feedback loop with CDK6 and inhibiting LRPPRC with the FDA-approved gossypol acetate overcomes CDK4/6 inhibition resistance.
- Wei Zhou
- Wenxi Wang
- Xiaohong Fang
